Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.24M | 1.43M | 1.29M | 1.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.24M | 1.43M | 1.29M | 1.28M |
| Cost of Revenue | -- | 518.20K | 468.40K | 419.10K | -- |
| Gross Profit | -- | 723.40K | 965.40K | 871.60K | -- |
| SG&A Expenses | -- | 845.60K | 548.60K | 751.80K | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 1.36M | 1.02M | 1.17M | 1.04M |
| Operating Income | -- | -122.20K | 416.80K | 119.80K | 244.10K |
| Income Before Tax | -- | -24.10K | -685.50K | -499.20K | -- |
| Income Tax Expenses | -- | 43.60K | 108.00K | -9.10K | -- |
| Earnings from Continuing Operations | -- | -67.70K | -793.50K | -490.10K | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -30.10K | -82.30K | -49.30K | -- |
| Net Income | -- | -97.80K | -875.80K | -539.40K | -4.38M |
| EBIT | -- | -122.20K | 416.80K | 119.80K | 244.10K |
| EBITDA | -- | -102.90K | 435.10K | 137.10K | 247.90K |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | -0.03 |
| Normalized Basic EPS | -- | 0.00 | 0.00 | 0.00 | -- |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | -0.03 |
| Normalized Diluted EPS | -- | 0.00 | 0.00 | 0.00 | -- |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |